Chinese biopharmaceutical firm RemeGen announced on Tuesday the completion of over $100 million in a new funding round jointly led China-based biomedical venture capital firm Lilly Asia Ventures, and Hong Kong’s healthcare investment fund Lake Bleu Capital.
Start your deal-making journey now!
Subscribe now to enjoy unlimited access at just $59.
Premium coverage on private equity, venture capital, and startups in Asia.
Exclusive scoops from our reporters in nine key markets.
In-depth interviews with industry leaders shaping the ecosystem.
Already a Subscriber? Log in
Contact us for corporate subscriptions at subs@dealstreetasia.com